These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29244542)

  • 1. Differential long-term medication impact on executive function and delay aversion in ADHD.
    Rubio Morell B; Hernández Expósito S
    Appl Neuropsychol Child; 2019; 8(2):140-157. PubMed ID: 29244542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
    Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
    Bédard AC; Stein MA; Halperin JM; Krone B; Rajwan E; Newcorn JH
    J Child Psychol Psychiatry; 2015 Jan; 56(1):40-8. PubMed ID: 24942409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder.
    Wu CS; Shang CY; Lin HY; Gau SS
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):187-196. PubMed ID: 33890819
    [No Abstract]   [Full Text] [Related]  

  • 7. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
    Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
    Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine.
    Schulz KP; Bédard AV; Fan J; Hildebrandt TB; Stein MA; Ivanov I; Halperin JM; Newcorn JH
    J Am Acad Child Adolesc Psychiatry; 2017 Jul; 56(7):602-609.e2. PubMed ID: 28647012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
    Yildiz O; Sismanlar SG; Memik NC; Karakaya I; Agaoglu B
    Child Psychiatry Hum Dev; 2011 Jun; 42(3):257-69. PubMed ID: 21165694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine Reestablishes Long Term Potentiation in a Mouse Model of Attention Deficit/Hyperactivity Disorder.
    Piña R; Rozas C; Contreras D; Hardy P; Ugarte G; Zeise ML; Rojas P; Morales B
    Neuroscience; 2020 Jul; 439():268-274. PubMed ID: 31809728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records.
    Warrer P; Thomsen PH; Dalsgaard S; Hansen EH; Aagaard L; Wallach Kildemoes H; Rasmussen HB
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):354-61. PubMed ID: 26891424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naïve Children With Attention-Deficit/Hyperactive Disorder.
    Fu Z; Yuan J; Pei X; Zhang K; Xu C; Hu N; Xie R; Zhao Y; Wang Y; Yang L; Cao Q
    Int J Neuropsychopharmacol; 2022 Sep; 25(9):709-719. PubMed ID: 35524732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial.
    Taş Torun Y; Işik Taner Y; Güney E; İseri E
    Appl Neuropsychol Child; 2022; 11(4):567-578. PubMed ID: 32757634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reinforcement and Stimulant Medication Ameliorate Deficient Response Inhibition in Children with Attention-Deficit/Hyperactivity Disorder.
    Rosch KS; Fosco WD; Pelham WE; Waxmonsky JG; Bubnik MG; Hawk LW
    J Abnorm Child Psychol; 2016 Feb; 44(2):309-21. PubMed ID: 25985978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.
    Gau SS; Shang CY
    Int J Neuropsychopharmacol; 2010 Mar; 13(2):243-56. PubMed ID: 19849892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.
    Cubillo A; Smith AB; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
    Psychol Med; 2014 Feb; 44(3):633-46. PubMed ID: 23597077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test.
    Kratz O; Studer P; Baack J; Malcherek S; Erbe K; Moll GH; Heinrich H
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):81-9. PubMed ID: 22227291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.